CytoReason, Pfizer sign $110m extended AI-based drug development deal

By NS Healthcare Staff Writer

21 Sep 22

Pfizer has used CytoReason's biological models in its research to improve the understanding of the immune system and…

PharmaceuticalsDrug discovery

Valo Health acquires TARA Biosystems to create integrated cardiovascular platform

By NS Healthcare Staff Writer

07 Apr 22

The transaction will create a vertically integrated platform and cardiovascular disease franchise, which will support the discovery and…

PharmaceuticalsDrug discovery

Exscientia, Oxford TDI partner for Xcellomics drug discovery programme

By NS Healthcare Staff Writer

11 Mar 22

Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…

PharmaceuticalsDrug discovery

Pfizer extends collaboration with Israeli tech start-up CytoReason

By NS Healthcare Staff Writer

11 Feb 22

The US drugmaker has used several insights from the CytoReason’ platform, in several of its R&D programmes across…

PharmaceuticalsDrug discovery

Ventus Therapeutics raises $140m to advance drug discovery platform

By NS Healthcare Staff Writer

10 Feb 22

The investment round, jointly led by SoftBank Vision Fund 2 and RA Capital Management, will advance the company’s…

Patient CarePharmaceuticals and MedicinesDrug discovery

Novartis to acquire Gyroscope Therapeutics for up to $1.5bn

By NS Healthcare Staff Writer

23 Dec 21

The acquisition will enable Novartis to add Gyroscope’s investigational gene therapy, GT005, to its portfolio

PharmaceuticalsDrug discovery

Exscientia acquires precision medicine company Allcyte for €50m

By NS Healthcare Staff Writer

17 Jun 21

Allcyte’s platform anticipates the activity of cancer treatments using AI to analyse the activity of drugs in live…

PharmaceuticalsDrug discovery

Exscientia enters into AI drug discovery partnership with Bristol Myers

By NS Healthcare Staff Writer

20 May 21

The collaboration will deploy AI to advance the discovery of small molecule therapeutic drug candidates in multiple therapeutic…

PharmaceuticalsDrug discovery

Swiss firm Roivant Sciences to go public in $7.3bn deal

By NS Healthcare Staff Writer

04 May 21

The transaction will enable Roivant Sciences to become a public entity and is expected to be listed on…

PharmaceuticalsDrug discovery

Exscientia receives up to $525m funding to expand AI drug discovery capabilities

By NS Healthcare Staff Writer

28 Apr 21

Exscientia intends to use the funding to advance its pipeline through clinical testing along with expanding its technology…

PharmaceuticalsDrug discovery